Syndax Pharmaceuticals (SNDX) PT Lowered to $33 at JPMorgan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts SNDX Hot Sheet
Price: $11.47 -19.73%
Rating Summary:
18 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 25 | New: 12
Rating Summary:
18 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 25 | New: 12
Join SI Premium – FREE
JPMorgan analyst Anupam Rama lowered the price target on Syndax Pharmaceuticals (NASDAQ: SNDX) to $33.00 (from $36.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Syndax to present 19 abstracts on two drugs at ASH 2026 meeting
- Dynatrace Inc. (DT) PT Lowered to $60 at DA Davidson
- Syndax Reports Third Quarter 2026 Financial Results and Provides Business Update
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
